Pegylated liposomal doxorubicin (PLD) is an intravenous antineoplastic agent in which a polyethylene glycol layer surrounds the conventional doxorubicin-containing liposomes. This drug delivery system reduces cardiotoxicity and neutropenia and enhances efficacy, however the prolonged half-life of the drug favours some side effects such as palmar-plantar erythrodysestesia (PPE). PPE is a common cumulative dermatological toxic reaction associated to PLD, with occurrence rates of 29-49%; it may also be observed with conventional doxorubicin and other chemotherapeutics. It is clinically characterized by burning and painful erythematosus and edematous lesions that typically involve palms and soles. Less frequently, PPE may also occur on pre-existing skin disease and on body surfaces exposed to friction. We present the case of a 60-year-old woman with metastatic breast cancer who was treated with PLD at the dose of 50 mg/m2 of body surface area every 4 weeks and about 4 days after the third infusion of PLD developed multiple, intensely painful and burning erythematous-oedematous plaques and patches, with central flat bullae and erosions, only on the axillary areas, hips, inner side of the thighs, dorsal surface of the feet and interdigital space of the fingers.
Pegylated liposomal doxorubicin induced palmar-plantar erythrodysestesia in uncommon multiple sites: a case report.
CORAZZA, Monica;MINGHETTI, Sara;BORGHI, Alessandro;VIRGILI, Anna
2011
Abstract
Pegylated liposomal doxorubicin (PLD) is an intravenous antineoplastic agent in which a polyethylene glycol layer surrounds the conventional doxorubicin-containing liposomes. This drug delivery system reduces cardiotoxicity and neutropenia and enhances efficacy, however the prolonged half-life of the drug favours some side effects such as palmar-plantar erythrodysestesia (PPE). PPE is a common cumulative dermatological toxic reaction associated to PLD, with occurrence rates of 29-49%; it may also be observed with conventional doxorubicin and other chemotherapeutics. It is clinically characterized by burning and painful erythematosus and edematous lesions that typically involve palms and soles. Less frequently, PPE may also occur on pre-existing skin disease and on body surfaces exposed to friction. We present the case of a 60-year-old woman with metastatic breast cancer who was treated with PLD at the dose of 50 mg/m2 of body surface area every 4 weeks and about 4 days after the third infusion of PLD developed multiple, intensely painful and burning erythematous-oedematous plaques and patches, with central flat bullae and erosions, only on the axillary areas, hips, inner side of the thighs, dorsal surface of the feet and interdigital space of the fingers.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
